Doctors across the country face a growing crisis as low supplies of essential cancer drugs tighten the safety net for patients. The shortage centers on generic chemotherapy infusions, the backbone of treatment for a long list of cancers. Hospitals report gaps that could force rationing decisions.

Supply chain disruptions, coupled with rising demand, have left pharmacies unable to fill unfilled orders. Patients already juggling multiple treatments now confront uncertainty as critical infusions slip through the cracks. Clinics warn that missed doses could compromise survival rates and inflate overall healthcare costs.

The ripple effect extends beyond patients. Pharmaceutical manufacturers face pressure to increase production, while insurers brace for higher reimbursement claims. Regulatory bodies may intervene to stabilize markets, but current data show no immediate relief in the pipeline. Stakeholders await clear guidance before committing to new supply agreements.

Until the shortage resolves, hospitals must triage patients and prioritize life‑saving treatments. The crisis underscores the fragile balance between drug availability and patient outcomes. Investors watching the pharma sector will track how manufacturers respond to supply constraints and whether new contracts emerge to secure drug flow.